DHT, RIA, 100 tests

The procedure follows the basic principle of radioimmunoassay where there is competition between the radioactive and non-radioactive antigen for a fixed number of antibody binding sites. The amount of (I-125)-labeled analyte bound to the antibody is inversely proportional to the concentration of unlabeled analyte present. The separation of free and bound antigen is achieved by using a double antibody system.

Catalog # KIPI9900
Format RIA
Label I125
Size 100 tests
Sample Type Serum, Plasma
Sample Volume 100 µL of extracted sample
Controls 2 levels
Range 25-2500 pg/mL
Sensitivity 20 pg/mL
Pretreatment 300 µL of sample/ 40 min.
Incubation 30min at 37°C + 20min + 20min centrifugation
Shelf Life (weeks) 12

Due to local registration requirement, this product can not be sold in Canada, United States, Australia – without prior registration.

For Japan and Brazil, specific registration requirements are necessary. For more information, please contact: regulatory.affairs@diasource.be.

Documents - Download
Download "Instructions for Use" KIPI9900.pdf
Download "Material Safety Data Sheet" MSKIPI9900.pdf
Download catalogue "RIA" CATR.pdf
Download RIA Availability Calendar CALRIA21d.pdf
Bridging Science And Diagnostics
Choose my country

DIAsource ImmunoAssays (formerly BioSource), experienced diagnostic manufacturer of RIA-ELISA-LIA immunoassays, validation on automates, large scale production of Antibodies-Point of Care Tests.

Please select your country to see the most accurate content available in your area.